机构:[1]State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Cancer Center, Sun Yat-sen University, Guangzhou 510060, China其他部门华南肿瘤学国家重点实验室中山大学肿瘤防治中心[2]Department of Gynecological Oncology, Sun Yat-sen University Cancer Center, Guangzhou 510060, China临床科室妇科中山大学肿瘤防治中心[3]The First Affiliated Hospital of Guangdong Pharmaceutical University, Guangzhou 510060, China
BACKGROUND: To develop and validate a nomogram based on log of odds between the number of positive lymph node and the number of negative lymph node (LODDS) in predicting the overall survival (OS) and cancer specific survival (CSS) for epithelial ovarian cancer (EOC) patients. MATERIALS AND METHODS: A total of 10,692 post-operative EOC patients diagnosed between 2004 and 2013 were obtained from the Surveillance, Epidemiology, and End Results (SEER) database and randomly divided into training (n = 7,021) and validation (n = 3,671) cohorts. Multiple clinical pathological parameters were assessed and compared with outcomes. Parameters significantly correlating with outcomes were used to build a nomogram. Bootstrap validation was subsequently used to assess the predictive value of the model. RESULTS: In the training set, age at diagnosis, race, marital status, tumor location, stage, grade and LODDS were correlated significantly with outcome in both the univariate and multivariate analyses and were used to develop a nomogram. The nomogram demonstrated good accuracy in predicting OS and CSS, with a bootstrap-corrected concordance index of 0.757 (95% CI, 0.746-0.768) for OS and 0.770 (95% CI, 0.759-0.782) for CSS. Notably, in this population our model performed favorably compared to the currently utilized Federation of Gynecology and Obstetrics (FIGO) model, with concordance indices of 0.699 (95% CI, 0.688-0.710, P < 0.05) and 0.719 (95% CI, 0.709-0.730, P < 0.05) for OS and CSS, respectively. Using our nomogram in the validation cohort, the C-indices were 0.757 (95% CI, 0.741-0.773, P < 0.05, compared to FIGO) for OS and 0.762 (95% CI, 0.746-0.779, P < 0.05, compared to FIGO) for CSS. CONCLUSIONS: LODDS works as an independent prognostic factor for predicting survival in patients with EOC regardless of the tumor stage. By incorporating LODDS, our nomogram may be superior to the currently utilized FIGO staging system in predicting OS and CSS among post-operative EOC patients.
基金:
National Natural Science Foundation of China [81560423]; Science and Technology Project of Guangdong Province [2015B050501005, 2014B050504004]; Science and Technology Project of Xinjiang Autonomous Region
语种:
外文
被引次数:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2017]版:
大类|2 区医学
小类|2 区肿瘤学3 区细胞生物学
最新[2023]版:
无
第一作者:
第一作者机构:[1]State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Cancer Center, Sun Yat-sen University, Guangzhou 510060, China
共同第一作者:
通讯作者:
通讯机构:[1]State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Cancer Center, Sun Yat-sen University, Guangzhou 510060, China[2]Department of Gynecological Oncology, Sun Yat-sen University Cancer Center, Guangzhou 510060, China
推荐引用方式(GB/T 7714):
Xue-Lian Xu,Hao Cheng,Meng-Si Tang,et al.A novel nomogram based on LODDS to predict the prognosis of epithelial ovarian cancer[J].ONCOTARGET.2017,8(5):8120-8130.doi:10.18632/oncotarget.14100.
APA:
Xue-Lian Xu,Hao Cheng,Meng-Si Tang,Hai-Liang Zhang,Rui-Yan Wu...&Xiao-Feng Zhu.(2017).A novel nomogram based on LODDS to predict the prognosis of epithelial ovarian cancer.ONCOTARGET,8,(5)
MLA:
Xue-Lian Xu,et al."A novel nomogram based on LODDS to predict the prognosis of epithelial ovarian cancer".ONCOTARGET 8..5(2017):8120-8130